Showing 3941-3950 of 7512 results for "".
- NPF Launches Multimedia Resource Center for Health Care Providers Caring for Individuals with Psoriatic Diseasehttps://practicaldermatology.com/news/npf-launches-multimedia-resource-center-for-health-care-providers-caring-for-individuals-with-psoriatic-disease/2461008/The National Psoriasis Foundation (NPF) is committed to offering innovative ways for health care providers (HCPs) to stay up-to-date on the latest news and research related to psoriatic disease. As part of its five-year strategic plan to improve health outcomes for all living with the disease, in
- Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai’s Department of Dermatologyhttps://practicaldermatology.com/news/top-researcher-of-itch-and-inflammatory-skin-conditions-to-join-mount-sinais-department-of-dermatology/2461006/One of the top researchers worldwide studying itch and inflammatory skin conditions, Brian S. Kim, MD, MTR, FAAD, will join Mount Sinai Health System as Director of the newly established Mark Lebwohl Center for Neuroinflammation and Sensation. Dr. Kim will also be Vice Chair of Research of the Ki
- JAK Inhibitor Combo Shows Promise in Alopecia Areatahttps://practicaldermatology.com/news/jak-inhibitor-combo-shows-promise-in-alopecia-areata/2461002/Ritlecitinib and brepocitinib show significant improvement in scalp alopecia areata biomarkers, according to a phase 2a clinical trial published inthe Journal of Allergy and Clinical Immunology. Rese
- RoundTable Healthcare Partners Completes Sale of Revision Skincare and Goodier Cosmetics to Gryphon Investorshttps://practicaldermatology.com/news/roundtable-healthcare-partners-completes-sale-of-revision-skincare-and-goodier-cosmetics-to-gryphon-investors/2461000/RoundTable Healthcare Partners completed the previously announced sale of Revision Skincare and Goodier Cosmetics to Gryphon Investors. Terms of the transaction were not disclosed. Revision Skincare’s portfolio includes Nectifirm, Intellishade, D·E·J
- ASDSA Honorees Recognized for Engagement in Initiatives that Benefit Dermatologic Surgery and Patientshttps://practicaldermatology.com/news/asdsa-honorees-recognized-for-engagement-in-initiatives-that-benefit-dermatologic-surgery-and-patients/2460995/The American Society for Dermatologic Surgery Association (ASDSA) announced the recipients of its annual awards this week during the ASDS / ASDSA Virtual Annual Meeting. ASDSA is proud to recognize its members who contribute significant time and expertise advocating for patient safety,
- New International Recommendations for Treating Acne Scars with Energy-Based Deviceshttps://practicaldermatology.com/news/new-international-recommendations-for-treating-acne-scars-with-energy-based-devices/2460990/Energy-based devices are the first-line treatments for a variety of acne scars, according to new international consensus recommendations published in Lasers in Surgery and Medicine. For the first time
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Better Together: Castle Biosciences’ Full DecisionDx Portfolio to Be Interfaced with ModMed’s EMAhttps://practicaldermatology.com/news/better-together-castle-biosciences-full-decisiondx-portfolio-to-be-interfaced-with-modmeds-ema/2460982/Castle Biosciences, Inc’s full DecisionDx portfolio of dermatologic tests will be interfaces with EMA, ModMed’s electronic health records system, by year-end 2021 The interface is designed to enable dermatologic clinicians to order Castle’s De
- Skyrizi Improves PsA Signs and Symptomshttps://practicaldermatology.com/news/skyrizi-improves-psa-signs-and-symptoms/2460981/AbbVie’s risankizumab (SKYRIZI) showed greater improvements in psoriatic arthritis (PsA) signs and symptoms compared to treatment with placebo at week 24 in two Phase 3 clinical trials, according to research slated to be presented American College of Rheumatology (ACR) Convergence 2021.
- Study: Infection Rates in PsA Patients on Biologics Are Decreasinghttps://practicaldermatology.com/news/study-infection-rates-in-psa-patients-on-biologics-are-decreasing/2460979/Infection rates among people with psoriatic arthritis (PsA) taking biologics decreased from 2012 to 2017, according to new research presented at ACR Convergence, the American College of Rheumatology’s an